Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Shares Issued (2016 - 2025)

Myriad Genetics has reported Shares Issued over the past 17 years, most recently at -$2.7 million for Q4 2025.

Quarterly Shares Issued fell 193.1% to -$2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Dec 2025, down 99.83% year-over-year, with the annual reading at $5.9 million for FY2024, 94.98% down from the prior year.
Shares Issued was -$2.7 million for Q4 2025 at Myriad Genetics, down from $2.9 million in the prior quarter.
Over five years, Shares Issued peaked at $117.6 million in Q4 2023 and troughed at -$90.0 million in Q4 2021.
The 5-year median for Shares Issued is $2.7 million (2022), against an average of $11.3 million.
The largest YoY upside for Shares Issued was 8733.33% in 2021 against a maximum downside of 5100.0% in 2021.
A 5-year view of Shares Issued shows it stood at -$90.0 million in 2021, then skyrocketed by 102.67% to $2.4 million in 2022, then surged by 4800.0% to $117.6 million in 2023, then plummeted by 97.53% to $2.9 million in 2024, then plummeted by 193.1% to -$2.7 million in 2025.
Per Business Quant, the three most recent readings for MYGN's Shares Issued are -$2.7 million (Q4 2025), $2.9 million (Q4 2024), and $117.6 million (Q4 2023).